

AAMP – ADVANCED INTEGRATIVE ONCOLOGY

18 AMA Cat-1 CE / ND: WA & HI Cat-1 (9-Hours of which are Pharmacology)

*CONO & BC ND Credit Applied for

FRIDAY

7:00 – 8:00

Breakfast

MORNING THEME: Modifying Cancer Risks and the Cancer Stroma

8:00 – 8:15 **Jeremy Phillips** Welcome & Introductory Remarks

8:15 – 9:30 Dr. Anderson **The Tumor Microenvironment – Targets for Treatment and Prevention**

In this session Dr. Anderson will discuss the evolving data on the tumor microenvironment (TME) and its role in oncogenesis, normal cell recruitment, remission, and reoccurrence. The focus of this session will be to understand the structure and mechanics of the TME, relating that to potential opportunities for treatment or prevention strategies.

9:30 – 10:15 Dr. Herskowitz **Plasmapheresis: The Science, Clinical Impact and Lessons Learned in an Integrative Cancer Care Treatment Center**

The technology rapidly “drains the swamp”, with some immediate and objective detoxification effects, while reducing pro-inflammatory signals and, ultimately, an impact on the patient and their tumor burden. A focus on the broad science as well as “before and after” Stage IV cases will be discussed, as well as some of the important lessons we can derive from these observations.

10:15 – 11:00

Break

11:00 – 12:00 Dr. Smith **Managing Controllable Risks for Primary and Secondary Prevention – Breast Cancer and Beyond – Part-1**

In this session Dr. Smith will outline the uncontrollable and controllable risks for breast (and other) cancer. Using the knowledge of these factors to implement primary and secondary cancer prevention, Dr. Smith will outline targets the clinician can focus on during the phases of primary and secondary preventive therapies.

12:00 – 1:15

Lunch

AFTERNOON THEME: Managing and Mitigating Cancer Risk Factors

1:15 – 1:45 Dr. Paul Savage MD Lifespan

Serial TPE PlasmaXchange: Potential for Preventing Cancer (Non-CME)

Exploring the emerging role of Serial Therapeutic Plasma Exchange (TPE), and the patent-pending PlasmaXchange protocol, and its potential for preventing cancer. Drawing from clinical experience and recent scientific research, Dr. Savage outlines how repeated TPE treatments can reduce systemic inflammation, clear immunosuppressive factors, and remove circulating toxins and oncogenic proteins that drive cancer progression.

1:45 – 2:15 Dr. Michael Chapman Genova Diagnostics

Managing the Endocrine Pyramid – Optimizing Metabolic Health and Limiting Hormone-Mediated Cancer Risk (Non-CME)

2:15 – 3:00

Break

3:00 – 4:00 Dr. Smith **Managing Controllable Risks for Primary and Secondary Prevention – Breast Cancer and Beyond – Part-2**

In this session Dr. Smith will continue to outline the uncontrollable and controllable risks for breast (and other) cancer. Using the knowledge of these factors to implement primary and secondary cancer prevention, Dr. Smith will outline targets the clinician can focus on during the phases of primary and secondary preventive therapies.

4:00 – 4:30 Dr. Anderson **Managing Risk Factors: Cancer and Infectious Diseases – Is the Connection Real (and what do we do about it?)**

In this session Dr. Anderson will discuss the published evidence for a cancer – infectious connection and make connections to potential therapies to assist with this particular comorbidity in people with cancer. Connections to immunomodulation, regulation, targeted therapies, and repurposed drugs will be made.

4:30 – 5:15 Dr. Anderson **Managing Risk Factors: Diet Targets and Metabolic Flexibility**

Diet and cancer care can be a topic fraught with controversy and confusion. In this session Dr. Anderson will discuss the commonality that “metabolic flexibility” brings to patients who are using a spectrum of dietary interventions. A discussion of how metabolic flexibility can fit many diet types, how to assess a patients “flexibility”, and common features of therapeutic dietary interventions regardless of diet type.

5:15 – 6:00 **Clinical Panel – Primary and Secondary Cancer Preventive Strategies**

6:00 – 7:30 **Evening Reception**

SATURDAY

7:00 – 8:00

Breakfast

MORNING THEME: Cancer Assessment Options

8:00 – 8:50 Dr. Anderson **Oncology Patient Assessment Basics: Testing Strategies**

In this session Dr. Anderson will discuss entry level testing strategies to assess and follow disease in the patient with cancer. Tests that are predictive and part of typical standard testing make the base of cancer monitoring. These tests will be discussed and evaluated as to their actual usefulness, ability to incorporate into treatment plans, and predictive value. This discussion will set up the following discussions of precision cancer assessment.

8:50 – 9:00 Dr. Herskowitz **A word from our conference partners, ACAM**

9:00 – 9:45 Dr. Adrian **Mold and Environmental Toxins as hidden risk factors for carcinogenesis, immunosuppression, and microenvironment disruption – Part-1**

Mold and environmental toxins are often not clearly identifiable based on smell or sight and therefore they are commonly overlooked by patients and practitioners as contributors to the cancer process. In this lecture we will explore the ways in which these toxins disrupt immune function and cellular and genetic repair, create inflammation, and contribute to the hallmarks of cancer. Then we will discuss actually implementable strategies for you to identify these toxins and support your patients through their elimination. We will discuss strategies to use both during active treatment, as well as those that are best during primary or secondary prevention, so that you leave with tools that are immediately useful in your practice.

9:45 – 10:30

Break

10:30 – 11:30 Dr. Adrian **Mold and Environmental Toxins as hidden risk factors for carcinogenesis, immunosuppression, and microenvironment disruption – Part-2**

This session completes the two-part discussion on mold, environmental toxicants, and cancer.

11:30 – 12:15 Dr. Smith **Managing Cancer Treatment Side Effects**

In this session Dr. Smith will outline strategies for dealing with common cancer treatment related side effects. Assessing, predicting, and intervening to aid patient quality of life will be the focus of this talk.

12:15 – 1:30

Lunch

AFTERNOON THEME: Managing Cancer and New Directions

1:30 – 2:00 Dr. Matthew Halpert Immunocine

Dendritic Cell Discoveries Restore Relevance for Integrative Oncology (Non-CME)

Though known since the 1970's to be critically important within immunological responses, previous failures of Dendritic Cells in the clinic have led to the belief that they are unable to restore immunological dominance against tough targets, such as cancer. However, more recent discoveries have highlighted that dogmatic misunderstanding of intracellular Dendritic Cell mechanisms have actually significantly held back their physiological prominence in any such attempt to combat cancer.

2:00 – 2:30 Dr. Shaina Cahill NovelBiome

Transforming Cancer Care: The Potential of FMT and the Gut Microbiome in Oncology (Non-CME)

Discover how the gut microbiome influences cancer development, progression, and treatment outcomes, and explore the transformative potential of Fecal Microbiota Transplantation (FMT) in oncology. This presentation will highlight cutting-edge research on FMT's role in enhancing immunotherapy efficacy, reducing treatment-related toxicity, and restoring microbial balance, offering actionable insights for integrating microbial therapy into cancer care.

2:30 – 3:15

Break

3:15 – 4:15 Dr. Anderson **Dr. Anderson: Oncology Therapy Updates – Hydrogen, FMT, and beyond...**

In this session Dr. Anderson will summarize the data around specific integrative cancer therapies. He will discuss how they work, when they may be appropriate, and how to implement them. Therapies such as Hydrogen Gas, Fecal Microbial Transplants, and more will be outlined.

4:15 – 5:15 Dr. Goodyear **Paradigm Change in Integrative Oncology – New Directions**

Surgery, chemotherapy, and radiation are deeply rooted in warfare. Surgery was developed and advanced to manage battlefield trauma. Chemotherapy was born out of chemical warfare in World War I and World War II. Radiation exploded during the Manhattan Project of World War II. President Nixon declared war on cancer. Oncology treatments and vernacular have been dominated by war. Instead of victory, we have only perpetuated a legacy of changes in cancer demographics. Enough war! Medicine must return to its roots as both science and art. We must transform the medical framework. We need a paradigm change that can only be achieved by the bridge of Integrative Oncology.

5:15 – 6:00 **Clinical Panel – Precision Therapeutics and Next Steps**

6:00 – 7:30 **Evening Demonstration, Hors d'oeuvres & Interactive Workshops**

SUNDAY

7:30 – 8:30

Breakfast

MORNING THEME: Advanced Integrative Oncology-1

8:30 – 9:30 Dr. Adrian **Advanced Applications in Mistletoe therapy**

Dr. Adrian uses mistletoe in clinical practice on a regular basis. This session will review the advanced use of mistletoe in cancer care including intravenous and subcutaneous application. Clinical applications, best practices, and safety will be featured.

9:30 – 10:30 Dr. Anderson **Autologous Immunotherapies – What, Why, How?**

Dendritic cell therapies? NK cell enrichment? Tumor Infiltrating Lymphocytes (TILs)? LAK cells? TPE? We may have heard of these therapies, or may be incorporating these therapies. They seem to make a lot of clinical sense but can also be mysterious and confusing. In this session Dr. Anderson will break down the types of therapies, technical requirements to achieve them, and potential uses in cancer therapy. This session will also create a base for the following targeted therapies sessions.

10:30 – 11:15

Break

11:15 – 12:15 Dr. Goodyear **Breaking the Cancer Code - Next-Generation Innovations in Oncology**

The last one hundred years of Oncology have been dominated by the systemic to tumor approach. War has been waged on cancer and the body. The future of Oncology is the tumor to systemic approach. The immune system is the target, not for collateral damage, but for activation and targeting of cancer. The future will break the cancer code through precision: the right therapy, for the right patient, at the right

location, in the right combination, at the right time. The future is not something to hope for; the future is here.

12:15 – 1:15

Lunch

AFTERNOON THEME: Advanced Integrative Oncology-2

1:15 – 1:45 Dr. Goodyear **Breaking the Cancer Code - Next-Generation Innovations in Oncology Part-2**

Dr. Goodyear will finish the discussion of the tumor to systemic approach using case examples and clinical pearls. This session will end with a Q&A session related to this topic.

1:45 – 2:45 Dr. Goodyear **Un-program—Reprogram - The Unified Theory of Aging and Cancer**

The future of oncology is already taking shape today. However, we are also in the early stages of a new future. If cancer can reprogram elements like epigenetics, transcriptomics, proteomics, metabolism, and the immune system, then we have the potential to un-program and reprogram cancer as well. The term "disease" is more than just a label; it represents a complex interplay of processes. Aging and disease are not separate phenomena; rather, they are different expressions of the same underlying mechanisms. These processes are interconnected and intertwined through common characteristics, which pave the way for a unifying theory that links the origins of aging and disease to treatment applications. This perspective shifts the focus from warfare against disease to a more healing-oriented approach to disease, regeneration, and aging.

2:45 – 3:00

Brief Comfort Break

3:00 – 4:00 Dr. Anderson **Repurposed Medications in Oncology – Critical Updates**

How can antiparasitic, antibiotic, antifungal, autonomic, cholesterol, and other drugs potentially help in cancer care? Why would they even work? In this session Dr. Anderson will relate experience from twenty years of experience in the use of “repurposed” oncology drugs. Where do they fit in therapeutic order? How can we optimize them? When should they be implemented? And more.

4:00 – 4:30 **Clinical Panel – Targeted Therapies and Patient Management**

4:30

Closing Remarks & Adjourn